Recursion Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$26,082
$14,417
$13,794
$10,891
Gross Profit
14,003
1,318
-772
-12,590
EBITDA
-98,354
-89,669
-84,732
-93,514
EBIT
-97,669
-92,132
-109,130
Net Income
-95,675
-97,540
-91,373
-92,996
Net Change In Cash
26,082
14,417
13,794
10,891
Free Cash Flow
-60,787
-86,401
-108,953
-76,494
Cash
427,647
476,124
299,521
394,796
Basic Shares
282,583
242,196
236,019
233,158

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$44,575
$39,681
$10,000
$3,413
Gross Profit
1,988
-8,594
10,000
-59,906
EBITDA
-299,566
-233,971
-174,370
-81,703
EBIT
-323,968
-245,727
-182,775
-86,145
Net Income
-328,066
-239,421
-178,074
-87,882
Net Change In Cash
44,575
39,681
10,000
3,413
Cost of Revenue
28,182
Free Cash Flow
-300,332
-120,883
-198,412
-52,134
Cash
391,565
549,912
285,116
262,126
Basic Shares
207,853
175,537
170,272
165,791

Earnings Calls

Quarter EPS
2024-09-30
-$0.34
2024-06-30
-$0.40
2024-03-31
-$0.39
2023-12-31
-$0.42